巨噬細胞移動抑制因子(MIF)活性蛋白
Active Macrophage Migration Inhibitory Factor (MIF)
GIF; GLIF; MMIF; Glycosylation-Inhibiting Factor; L-dopachrome isomerase; L-dopachrome tautomerase; Phenylpyruvate tautomerase
- 編號APA698Hu02
 - 物種Homo sapiens (Human,人)相同的名稱,不同的物種。
 - 緩沖液成份20mM Tris, 150mM NaCl緩沖液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
 - 性狀凍干粉
 - 純度> 95%
 - 等電點6.6
 - 應(yīng)用Cell?culture;?Activity?Assays.
 - 下載英文說明書 中文說明書
 - 規(guī)格10μg50μg200μg1mg5mg
 - 價格¥ 1934¥ 4836¥ 9672¥ 29016¥ 72540
 - 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
 
活性實驗

Figure. The binding activity of MIF with MHCDG.
Macrophage migration inhibitory factor (MIF), also known as glycosylation-inhibiting factor (GIF), L-dopachrome isomerase, or phenylpyruvate tautomerase is a protein classified as an inflammatory cytokine. MIF is an important regulator of innate immunity. It involved in cell-mediated immunity, immunoregulation, and inflammation. MIF plays a role in the regulation of macrophage function in host defense through the suppression of anti-inflammatory effects of glucocorticoids. This lymphokine and the JAB1 protein form a complex in the cytosol near the peripheral plasma membrane, which may indicate a role in integrin signaling pathways. Besides, Major Histocompatibility Complex Class II Invariant Chain (MHCDG) has been identified as an interactor of MIF, thus a binding ELISA assay was conducted to detect the interaction of recombinant human MIF and recombinant human MHCDG. Briefly, MIF were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to MHCDG-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-MIF pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of MIF and MHCDG was shown in Figure 1, and this effect was in a dose dependent manner.
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) | 
| APA698Hu02 | 巨噬細胞移動抑制因子(MIF)活性蛋白 | Cell?culture;?Activity?Assays. | 
| APA698Hu01 | 巨噬細胞移動抑制因子(MIF)活性蛋白 | Cell?culture;?Activity?Assays. | 
| RPA698Hu02 | 巨噬細胞移動抑制因子(MIF)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| RPA698Hu01 | 巨噬細胞移動抑制因子(MIF)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| PAA698Hu06 | 巨噬細胞移動抑制因子(MIF)多克隆抗體 | WB | 
| PAA698Hu01 | 巨噬細胞移動抑制因子(MIF)多克隆抗體 | WB; IHC | 
| PAA698Hu02 | 巨噬細胞移動抑制因子(MIF)多克隆抗體 | WB; IHC | 
| MAA698Hu22 | 巨噬細胞移動抑制因子(MIF)單克隆抗體 | WB; IHC; ICC; IP. | 
| SEA698Hu | 巨噬細胞移動抑制因子(MIF)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. | 
| LMA698Hu | 巨噬細胞移動抑制因子(MIF)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. | 
| KSA698Hu01 | 巨噬細胞移動抑制因子(MIF)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". | 
參考文獻
| 雜志 | 參考文獻 | 
| Kidney International | Targeted reduction of advanced glycation improves renal function in obesity[PubMed: 21412218] | 
| The Journal of Immunology | Macrophage Migration Inhibitory Factor Plays a Role in the Regulation of Microfold (M) Cell-Mediated Transport in the Gut[Jimmunol: 5673] | 
| The Journal of Endocrinology | Involvement of exercise-induced macrophage migration inhibitory factor in the prevention of fatty liver disease[PubMed: PMC3757527] | 
| The Journal of Immunology | Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice[PubMed: PMC3466372] | 
| Diabetologia | Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes[Pubmed:24957662] | 
| BioMed Research International | The Potential Role of Polymethyl Methacrylate as a New Packaging Material for the Implantable Medical Device in the Bladder[PubMed: 25705692] | 
| Diabetologia | Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.[pubmed:28160092] | 
| Life Sciences | Protective effect of chlorogenic acid on the inflammatory damage of pancreas and lung in mice with l-arginine-induced pancreatitis [pubmed:28919396] | 
| Scientific Reports | Cytokine MIF Enhances Blood-Brain Barrier Permeability: Impact for Therapy in Ischemic Stroke[Pubmed:29335619] | 
| Ocular?Immunology?and?Inflammation | Immune Response and Mechanisms of IFN-γ in Administration for Keratomycosis[Pubmed: 30307777] | 
| International Journal of Immunopathology and Pharmacology | Effect of voluntary running on expression of myokines in brains of rats with depression[Pubmed: 30834799] | 
| Biomarkers in Heart Failure and Associated Diseases | Biomarkers in Heart Failure and Associated Diseases[] | 
| Science China-Life Sciences | Autophagy mediates the secretion of macrophage migration inhibitory factor from cardiomyocytes upon serum-starvation[Pubmed: 31209799] | 
| Folia Morphologica | Beneficial effects of voluntary over forced exercise on skeletal muscle structure and myokines expression[Pubmed: 31802473] | 
| Biomed Pharmacother | Deletion of macrophage migration inhibitory factor ameliorates inflammation in mice model severe acute pancreatitis[Pubmed: 32062385] | 
| Sci Rep | Association between MIF gene promoter rs755622 and susceptibility to coronary artery disease and inflammatory cytokines in the Chinese Han population[33850223] | 
| Commun Biol | Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes[Pubmed:35115654] | 




